排序方式: 共有27条查询结果,搜索用时 11 毫秒
1.
ICU医院感染影响因素分析 总被引:1,自引:0,他引:1
目的分析探讨重症监护病房(ICU)住院患者发生医院感染的相关因素,为降低医院感染率制定措施。方法调查2010年1月-2013年10月ICU 1 718例住院患者临床资料,以单因素和logistic回归分析医院感染的发生率及相关因素。结果通过单因素分析,患者的性别(χ2=20.038,P<0.001)、病情分级(χ2=60.122,P<0.001)、基础疾病数量(χ2=79.123,P<0.001)和住院时间(χ2=730.309,P<0.001)以及医源性的免疫制剂(χ2=24.754,P<0.001)、动静脉插管(χ2=151.528,P<0.001)、泌尿道插管(χ2=25.752,P<0.001)、使用呼吸机(χ2=81.348,P<0.001)、气管插管(χ2=6.691,P=0.010)、气管切开(χ2=483.914,P<0.001)等因素是医院感染的影响因素;通过多因素分析,病情分级(P=0.026)、住院时间(P<0.001)、气管插管(P=0.004)和气管切开(P<0.001)均为医院感染的影响因素。结论影响医院感染的因素有很多,尤其是重症监护病房,要降低医院感染的概率需要从患者和医院各个方面采取多种措施。 相似文献
2.
3.
目的 研究HER-2和TOP2A对乳腺癌细胞系SK-Br-3的放射敏感性影响,并探讨二者联合作用,为临床研究奠定基础。方法 分别构建表达HER-2或TOP2A siRNA的重组质粒,并使用lipofectamine 2000将其转染至乳腺癌细胞SK-Br-3中,敲降HER-2和TOP2A的基因表达。2 d后利用蛋白印迹法检测干扰效果,利用流式细胞仪和MTT法分别检测放射处理后细胞凋亡和增殖变化,并检测凋亡和增殖相关蛋白Caspase-3、Bcl-2、Ki-67表达变化。克隆形成实验检测放射敏感性。结果在乳腺癌细胞SK-Br-3中敲降HER-2和TOP2A的表达,放射处理后细胞凋亡率升高,增殖率降低。凋亡标志蛋白活化的Caspase-3表达升高,凋亡抑制蛋白Bcl-2表达降低。细胞增殖标志蛋白Ki-67表达降低。同时敲降HER-2和TOP2A两个基因时促进凋亡和抑制增殖及克隆形成的作用增强,表明这两个基因存在协同效应。结论 敲降HER-2和TOP2A基因在乳腺癌细胞SK-Br-3中的表达后,乳腺癌细胞的放射敏感性提高,细胞凋亡率升高,细胞增殖率降低,克隆形成率降低,且2基因存在协同效应,作用机制可能与Caspase-3、Bcl-2有关的凋亡通路及细胞增殖蛋白Ki-67有关。 相似文献
4.
目的探讨姐妹染色单体互换(SCE)技术在小儿急性白血病(AL)诊断中的作用。方法采用SCE技术检测40例不同时期AL患儿,包括初发组20例(其中检测外周血、骨髓各10例),部分缓解(PR)组10例检测骨髓,完全缓解(CR)组10例检测骨髓。另选健康儿童20例作为健康对照组,检测外周血。骨髓和外周血采用SCE技术制作标本,每例分析40个中期分裂相,计数SCE频率。结果初发组骨髓和外周血SCE频率无显著性差异(Pa〉0.05),初发组和健康对照组比较,SCE频率增加,有极显著性差异(Pa〈0.01)。初发组和PR组比较,SCE频率无显著性差异(Pa〉0.05),初发组与CR组比较,SCE频率下降,有极显著性差异(Pa〈0.01);PR组和CR组比较,SCE频率下降,有极显著性差异(Pa〈0.01)。结论SCE频率变化与疾病的严重程度呈平行关系,SCE在小儿AL中可用来进行协助诊断。 相似文献
5.
Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy. 相似文献
6.
目的了解原癌基因C-met在人乳腺癌组织中表达的规律,以及这种规律与肿瘤生物学行为的关系。方法应用SP免疫组织化学方法,检测60例乳腺浸润性导管癌,20例乳腺纤维腺瘤组织中原癌基因C-met的表达情况。结果原癌基因C-met在60例乳腺浸润性导管癌表达阳性率为65.00%,其与肿瘤组织学分级、临床分期、淋巴结转移相关(P<0.05),而与年龄、月经情况、肿瘤大小无关(P>0.05)。C-met在乳腺癌组织中的表达显著高于乳腺纤维腺瘤组织(P<0.010)。结论原癌基因C-met过度表达与乳腺癌的转移密切相关,对乳腺癌的发生发展起重要作用,对指导临床预防治疗有一定意义。 相似文献
7.
Objective To investigate the efficacy of TTC and FTC regimens as neoadjuvant chemotherapy in breast cancer. Methods Collecting clinical data of 325 patients received neoadjuvant chemotherapy with TIC and FTC regimens from June 2004 to April 2008, among them 138 patients received neoadjuvant chemotherapy with TTC regimen in one group, and 187 patients received neoadjuvant chemotherapy with CTF regimen in the other group. The expression of Topo Ⅱ a in specimen of 325 patients before neoadjuvant chemotherapy were detected by immunohistochemical method. Results Among the 325 cases of neoadjuvant chemotherapy, the overall response rate (RR) was 87.7 % in TIC arm and 67.4 % in FTC arm (P=0.000), but in the group of Topo Ⅱ a(+) Her-2(-), the overall response rate (RR) was 87.8 % in TTC arm and 79.4 % in FTC arm (P=0.266), and in the groups of Topo Ⅱ a(-), there was statistical significance; the pathologic complete response rate (pCR) was 13.7 % in TIC ann and 11.2 % in CTF ann (P=0.491). Conclusion TIC regimen is superior to FTC regimen in the response rate of neoadjuvant chemotherapy, but patients with negative expression of Topo Ⅱ a may get more benefits from 9eoadjuvant taxane and anthracycline chemotherapy. 相似文献
8.
9.
10.